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Characterisation of Neisseria gonorrhoeae in semen
during urethral infection in men
Susan F Isbey, Timothy M Alcom, Rachael H Davis, Julie Haizlip, Peter A Leone,
Myron S Cohen
Objective: To determine the number of Neisseria gonorrhoeae organisms in urine and semen in
men with gonococcal urethritis, and to compare selected phenotypic characteristics of organisms
harvested from the urethra and semen.
Design: Samples from two groups of subjects were examined. Patients with symptomatic ure-
thritis receiving treatment at an STD clinic, as well as six subjects with experimental urethritis.
Semen and urine specimens were obtained after the urethral exudate was sampled.
Results: Using quantitative cultures, we found an average of 6 x 106 gonococci in urine or
semen of 17 men with symptomatic urethritis seeking treatment at an STD clinic, and 2 x 104
gonococci in secretions of six male subjects with early experimental infection. Gonococcal outer
membrane opacity (Opa) proteins and lipo-oligosaccharide (LOS) recovered from urine and
semen of these subjects were very similar.
Conclusions: Men with symptomatic gonorrhoea excrete a large number of gonococci in semen
which is not affected by the duration of symptoms. The similar phenotype of organisms in urine
and semen suggests the bacteria come from the same compartment. These data help to explain the
efficiency of gonococcal transmission from men to their partners, and identify an appropriate
target for a preventative vaccine or immunotherapy designed to reduce the inoculum in infected
patients.
(Genitourin Med 1997;73:378-382)
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Neisseria gonorrhoeae is an obligate human
mucosal pathogen that causes urethritis in the
male and cervicitis in the female.' Gonorrhoea
is the most frequently reported bacterial infec-
tion in the United States,2 and more than 62
million cases of gonorrhoea occurred world-
wide in 1995.3 About 10% to 20% of infected
women with gonococcal cervicitis develop
pelvic inflammatory disease (PID),45 which
can lead to tubo-ovarian abscess, ectopic preg-
nancy, and sterility.' There is also evidence
that gonococcal infection facilitates transmis-
sion of the human immunodeficiency virus
(HIV).6 7
A variety of factors affect the efficiency of
transmission of STD pathogens,8 and these
factors are probably quite different among
males and females. N gonorrhoeae is transmit-
ted from females to their male partners
approximately 20% of the time after a single
episode of sexual intercourse, and 80% of the
time after four episodes of intercourse.9 Male
to female transmission of N gonorrhoeae is
more efficient; 50-90% of exposed women
develop infection after a single episode of vagi-
nal intercourse.'0 The purulent urethral
exudate characteristic of gonorrhoea is infec-
tious," and it is likely that bacteria found in
semen play a role in the transmission of dis-
ease from males to their sexual partners.
Successful infection with gonococci
depends on the number of bacteria in the
inoculum,"2"3 and bacterial outer membrane
components which allow attachment and inva-
sion of epithelial cells (reviewed in Cohen and
Sparling'4). Specifically, outer membrane
opacity (Opa) proteins and lipo-oligosaccha-
rides side chains are believed to play a critical
role in gonococcal attachment and invasion of
mucosal epithelial cells.'4 To address biologi-
cal factors influencing the efficiency of trans-
mission of N gonorrhoeae we determined the
number of gonococci in the urine and semen
of men with natural and experimentally
induced urethral infection. We also examined
several outer membrane components believed
to be important during gonococcal infection.
Materials and methods
Two cohorts were included in this study;
patients seen at the Wake County STD Clinic
in Raleigh, North Carolina'5 and volunteer
subjects enrolled in a study of experimental
gonococcal urethritis conducted in the
General Clinical Research Center at the
University of North Carolina.'2 Permission for
the study of both cohort groups was obtained
from the Committee on the Protection of the
Rights of Human Subjects at the University of
North Carolina at Chapel Hill. Patients visit-
ing the STD clinic were eligible to participate
in the study if they were 18 years of age or
older, and presented to the clinic with sympto-
matic gonococcal urethritis. Inclusion in the
study was based on presence of Gram negative
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the urethral exudate. Patients with known
HIV disease were excluded from participation.
Subjects were asked to respond to a brief sexual
history questionnaire, undergo urethral swab,
and give full void urine and semen specimens
for culture of gonococci. All responses to
questions and experimental results were confi-
dential. Participation in the experiment did
not affect treatment of subjects, who were
counselled by a physician care provider (PAL
or SFI) and given ceftriaxone, ciprofloxacin or
cefixime, and doxycycline. All subjects were
reimbursed for their participation in the study.
We have developed an experimental model
of human gonococcal urethritis to examine
gonococcal virulence factors and as a para-
digm for vaccine testing.12 Subjects participat-
ing in studies of experimental urethral
gonorrhoea were recruited through advertise-
ment, and admitted to the General Clinical
Research Center. Procedures for the prepara-
tion of the gonococcal strain, urethral inocula-
tion of subjects, and their observation during
the course of the study have been described.'2
Subjects were inoculated with gonococcal
strain FA1090 variant A21. A piliated, Opa
phenotype was selected. Subjects were inocu-
lated through a No 8 French paediatric
catheter moistened with sterile saline. 12 All
subjects were treated with ceftriaxone with the
onset of a urethral discharge (and detection of
organisms by Gram's stain as described
above), or before release from the unit. Semen
was collected from these subjects after collec-
tion of urine.
QUANTIFICATION OF GONOCOCCI IN URINE AND
SEMEN
Full void, clean catch urine specimens were
collected in sterile centrifuge bottles at the
time of enrolment (WCHD subjects) or 21
and 45 hours after urethral inoculation (exper-
imental urethritis subjects). Sample prepara-
tion, cultures, and enumeration of the
gonococci in urine and semen were performed
as previously described.'5 Briefly, urine speci-
mens were centrifuged at 1500 x g for 10
minutes. The supernatants were decanted and
the pellets containing the gonococci were
resuspended in 600 gl of gonococcal culture
broth (1-5% w/v proteose peptone, 86 mM
NaCl, 5.7 mM KH2P04, 29.9 mM K2HPO4),
serially diluted from 10 - to 10-6 and dupli-
cate plated on selective commercially prepared
media (Martin-Lewis media, BBL,
Cockeysville, MD, USA). Vancomycin (VCN
selective supplement, Unipath Ltd,
Hampshire) was added to this selective media.
To assure the recovery of vancomycin sensi-
tive gonococci all specimens were also plated
on chocolate media (BBL, Cokeysville, MD,
USA). Plates were placed in candle extinction
jars, transported to a 5% carbon dioxide incu-
bator at 37°C, examined for growth, and
counted at 24 and 48 hours.
In order to document our ability to recover
gonococci from semen, specimens obtained by
masturbation from healthy volunteers in the
fertility clinic were "spiked" in the laboratory
with gonococcal strain FA109OA21 (the strain
used to infect experimental subjects as
described above). Numbers of organisms
recovered at various time points were deter-
mined. Two 1.5 ml aliquots of a log phase
broth culture of N gonorrhoeae (each contain-
ing 1. 8 x 107 colony forming units (CFU)
were centrifuged at 12 000 x g for 30 seconds
and the supernatants decanted. The pellets
were resuspended in 100 ptl ofGCB broth and
inoculated into either 1.0 ml of normal human
semen or gonococcal culture broth (GCB)
prepared as previously described.'5 These sus-
pensions were rotated at 12-15 rpm in a 5%
carbon dioxide incubator at 37°C and the
number of CFU recovered from the suspen-
sion at 30 minutes and at 1, 4, and 20 hours
after inoculation was determined. There was
no significant difference in the numbers of
gonococci recovered from semen compared
with GCB for up to 4 hours of incubation.
Significantly more bacteria were recovered
from GCB compared with semen after 20
hours (data not shown).
Semen specimens from infected individuals
were obtained immediately after urine speci-
mens in sterile specimen cups. Fresh semen
specimens were examined for viscosity and
allowed to liquefy for up to 20 minutes at
room temperature before dilution plating. In
control experiments with split semen speci-
mens from WCHD volunteers there were no
significant differences between the numbers of
viable organisms recovered from the semen
plated immediately versus the liquefied sample
obtained 20 minutes after collection (data not
shown). Therefore, liquefied semen was used
in all studies since it was easier to pipette accu-
rately. For each volunteer, gonococci isolated
from swab, urine, and semen samples were
placed in trypticase soy broth medium con-
taining 25% glycerol and frozen at -70°C.
DETERMINATION OF OPACITY PROTEIN
EXPRESSION
Monoclonal antibodies (mAbs) specific for
Opa proteins of strain FA109016'7 were used
in colony and western blots to determine Opa
expression of variants recovered from experi-
mentally inoculated volunteers as previously
described.'6 17 Suspensions of individual
colonies from the primary isolation plates were
spotted onto multiple nitrocellulose mem-
branes (Schleicher and Schuell, Keene, NH,
USA) and probed with Opa specific mAbs.
The monoclonal antibodies used to differenti-
ate Opa proteins expressed in strain FA1090
do not reliably differentiate Opa protein
expression in wild type gonococcal strains.
Therefore, Opa proteins from wild type gono-
cocci were identified by heat modifiability in
SDS-PAGE analysis using the Laemmli buffer
system.'8 19 Gonococci isolated from frozen
suspensions of urine and semen samples of
WCHD subjects were streaked on selective
media containing vancomycin, colistin, and
nystatin (VCN plates) or onto chocolate
media and grown overnight. Outer mem-
branes were prepared by suspension of bacte-
ria in 1 ml lithium acetate buffer (0.2 M
lithium chloride, 0.1 M sodium acetate,
379
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B taining 5% carbon dioxide. Colonies were
_B scraped from the plate and suspended in
Laemmli solubilisation buffer'8 containing 4%
SDS, 10% glycerol, 10% 2-mercaptoethanol,
A A A and 0.125 M Trizma base (pH 6.8) and
A AA A A heated to 100°C for 10 minutes. Twenty five g
A A of proteinase K (Gibco BRL, Gaithersburg,
A
A A MD, USA) were added to the cell lysate and
A heated to 60°C for 1 hour. LOS of each sample
were separated by SDS-PAGE using the
Laemmli buffer system'8 with a 21% resolving
gel and a 4% stacking gel. Electrophoresis was
carried out at 35 mA constant current. After
soaking the gels in a solution of 10% acetic
acid and 40% ethanol overnight, the LOS in
the gels were oxidised by incubating the gels in
2 3 4 5 6 7 8 a 1% solution of potassium dichromate for 30
minutes. LOS were then visualised by silver
(WCHD STD subjects) staining using the method of Tsai andFrasch.'0 Individual LOS species of most
gonococcal isolates were identified by SDS-
D PAGE. Some isolates were further analysed by
immunochemical analysis using monoclonal
antibodies (mAbs) 3F1 1, 1-1-M, 4C4, and







A A We quantitated Neisseria gonorrhoeae in urine
and semen specimens of subjects with sympto-
matic or experimental gonococcal urethritis.
For 17 subjects with symptomatic gonococcal
urethritis at the WCHD STD clinic, total
gonococcal CFU in urine ranged from 3.7 x
104 to 2.6 x 107,with an average of 6-1 x 106
CFU (fig 1). Urine was collected before semen
specimens for all but two subjects. The total
1 2 3 4 5 6 7 8 CFU in semen ranged from 6.9 x 104 to 6-1
Days of symptoms x 107, with an average of 7-0 x 106 CFU.
(WCHD STD subjects) There was no correlation between the number
mber of colony forming units (CFU) in urine or of CFU present in urine or semen and sample
1 urethritis or 17 STD clinic patients. Circles are volume or the duration of symptoms (data not
C) specimens in patients with experimental shown) for an individual volunteer. However,
ine (B) and semen (D) specimens in STD clinic
s overlap. Nine patients providing urine samples there was a good correlation between the
15 number of CFU in the semen and urine for
each WCHD subject (linear correlation coeffi-
cient, r = 0.66).
Six subjects inoculated participating in our
A EDTA, pH 5.8) which was passed 15 studies of experimental gonococcal urethritis"2
through a 22 gauge needle. Cellular became infected within 45 hours. The average
is was removed by centrifugation at 8000 gonococcal CFU recovered from the urine for
for 15 minutes.19 The supernatant was three volunteers treated at 21 hours (subjects
centrifuged at 100 000 x g for 2 hours at 40, 42, and 43) was 1.8 x 103 per void (fig 1).
Pellets were resuspended in 100 pul The average number of CFU in semen speci-
uised water, vortexed for 1 minute, and mens obtained from 21 to 45 hours after inoc-
ifuged again at 14 000 x g for 1 minute. ulation was 1.7 x 104 and was independent of
Twenty g1 aliquots of the supernatants were
solubilised at 100°C for 10 minutes or 37°C
for 1 hour and electrophoresed in 11% SDS-
polyacrylamide gels with Laemmli buffers'9 at
100 V for 2-3 hours. Gels were silver stained
using the method of Tsai and Frasch.'0
DETERMINATION OF LIPO-OLIGOSACCHARIDE
(LOS) PHENOTYPE
LOS of gonococcal isolates was examined by a
modification of the method of Hitchcock and
Brown.21 Frozen primary isolates were subcul-
tured onto GC agar plates and allowed to
grow overnight at 37°C in an atmosphere con-
the semen volume.
SURFACE CHARACTERISTICS OF GONOCOCCI IN
URINE AND SEMEN
A large number of gonococci were recovered
from semen even after swabbing of urethral
exudate and full void urination. This observa-
tion led us to ask whether organisms recovered
from urine and semen are similar or different
in the expression of variable surface compo-
nents such as LOS or Opa proteins.'4 Opa pro-
teins are antigenically variable, heat modifiable
outer membrane proteins with apparent mole-
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appear to play a role in the association of
gonococci with epithelial cells.23
A panel of monoclonal antibodies (mAbs)
reactive with the Opa proteins of strain
FA109016 17 enabled us to characterise the Opa
proteins expressed by gonococci isolated from
urine and semen specimens during experimen-
tal infection. Following experimental infection
with an inoculum which was 89% Opa nega-
tive, the majority of isolates recovered from
urine and semen of three subjects over 1 to 2
days expressed Opa proteins. For a given vol-
unteer the repertoire of Opa proteins
expressed by bacteria recovered from urine or
semen was similar, and one or more of the
major Opa proteins (expressed by > 20% of
the bacteria analysed) were the same (data not
shown). FA1090 Opa protein mAbs are not
specific for wild type gonococcal Opa proteins.
Accordingly, Opa proteins from urine and
semen samples of the WCHD isolates were
compared by SDS-PAGE analysis. Opa pro-
teins were identified by apparent molecular
radius and heat modifiability. In six subjects
the Opa proteins expressed in the urine and
semen isolates were indistinguishable. In 1/7
subjects the Opa proteins expressed in the
semen were different in size and number from
those in urine (fig 2; lanes 3 and 4).
LOS is believed to evoke an inflammatory
response and is a target for bactericidal anti-
bodies.'4 The LOS phenotype may affect the
infectivity of the organism.'3 24 Examination of
LOS from gonococci in urine and semen sam-
ples of eight WCHD clinic subjects and three
experimental volunteers revealed no differ-
ences in apparent mobility of LOS by gel elec-
trophoresis and/or antibody binding.
Discussion
The bacterial inoculum required to produce
gonorrhoea in males or females is not known.
In experimental models of male urethritis
(reviewed in Cohen et al 12) the dose used to
produce infection was 102 to 108 CFU,
depending on the strain and variant used, and
the experimental procedure employed. 12 13 24 25
In all, 102 to 1 07 organisms have been recov-
ered from cervical washings of female contacts
of males with gonococcal urethritis.26 In the
present study we examined numbers and some
antigenic characteristics of gonococci in urine
and semen. Symptomatic males with gonococ-
cal urethritis have an average of 106 CFU in
semen (obtained after swabbing the distal ure-
thra and full void urination). This number was
independent of either semen volume or dura-
tion of symptoms. It seems likely that the large
concentration of gonococci in semen helps to
explain the efficiency of transmission from
men to their partners.10 In our experimental
model of early human gonococcal urethritis,
an average of 104 organisms were present in
urine and semen, most probably due to the
short duration of infection in the experimental
subjects. 12
Outer membrane structures have been
implicated as virulence factors.'42324 Variation
of LOS24 and Opa proteins'7 27 recovered from
different infected sites and at different times in
the same patients have been described. In
addition, in the current study gonococci were
recovered from semen after urethral swabbing
and urination, suggesting that gonococci in
semen could reside in a separate compart-
ment. However, Opa proteins and LOS
expressed in urine and semen for each subject
were nearly always the same, thereby suggesting
a common mucosal source.
Gonococcal infections are common in both
developed and developing countries.23
Gonorrhoea facilitates both the infectiousness
and acquisition of HIV.78 Control of the
spread of gonorrhoea is a critical global public
health agenda. Such control can be realised in
part by behavioural changes including reliable
use of condoms, and by aggressive usage of
single dose antibacterial therapy in patients,
their partners,28 and in some cases whole com-
munities.29 Nevertheless, development of a
gonococcal vaccine remains critical.30 A gono-
coccal vaccine could be used to protect sus-
ceptible people at risk, and/or reduce the
inoculum excreted in patients with gonococcal
infection, so as to reduce the efficiency of
transmission. Information regarding numbers
of organisms excreted in the semen and the
antigenic characteristics of organisms in vivo
should prove helpful in these vaccine develop-
ment efforts.
Results presented in part at the 33rd Interscience Conference
on Antimicrobial Agents and Chemotherapy, 17 October 1993,
New Orleans, LA (Abstract No 7).
Informed consent was obtained from all subjects enrolled in
this study. The study was approved by the Committee on the
Protection of the Rights of Human Subjects at the University of
North Carolina at Chapel Hill and the UNC Institutional
Review Board. Human experimentation guidelines of the US
Department of Health and Human Services were followed in
the conduct of the clinical research.
There is no conflict of interest related to this paper.
This work was supported by Public Health Service Grant
UO1 AI-331496 from the National Institute of Allergy and
Infectious Diseases and the Verne S Caviness Clinical Research
Center (No MO1RROO046).
The authors would like to thank Penny M Drown, Larry M
Chamiga, and Leesa Whicker for technical assistance, Dr Ann E
Jerse for methodological advice, and Dr Janne G Cannon for
valuable suggestions, Opa protein analysis, and critical review
of the manuscript.
1 Hook EW III, Handsfield HH. Gonococcal infections in
the adult. In: Holmes KK, Mardh PA, Sparling PF,
Wiesner PJ, eds. Sexually transmitted diseases. New York:
McGraw-Hill, 1990:149-65.
Figure 2 SDS-PAGE




(lanes 1 and 2) and 5
(lanes 3 and 4) urine (U)
and semen (S) samples.
The location of the porin
protein (PI) is indicated on
each gel as well as the
approximate location of the
Opa proteins. All proteins
were solubilised at 1000C
before electrophoresis.
Gonococci isolatedfrom
volunteer 8 expressed a
single Opa protein (lane
3), whereas urine isolates
(lane 4) expressed two
different Opa proteins.
Lane 5 contains protein
molecular weight standards
with the location of the
29 kD and 43 kD proteins
marked.
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